Case Report

The Efficacy of Anti-Tumor Necrosis Factor Therapy in Cryopyrin-Associated Periodic Syndromes: A Report of Two Cases

Fatemeh Tahghighi,1,2,3 Mahdieh Vahedi,3,4 Nima Parvaneh,1,2 Mohammad Shahrooei,5 and Vahid Ziaee1,2,3,6

1Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
2Children’s Medical Center, Pediatrics Center of Excellence, Tehran, Iran
3Pediatric Rheumatology Iranian Society, Tehran, Iran
4Department of Pediatrics, Mashhad University of Medical Sciences, Mashhad, Iran
5Department of Microbiology and Immunology, Laboratory of Clinical Bacteriology and Mycology, KU Leuven, Leuven, Belgium
6Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Vahid Ziaee; ziaee@tums.ac.ir

Received 10 November 2021; Revised 4 February 2022; Accepted 9 February 2022; Published 2 March 2022

Academic Editor: Balraj Mittal

Copyright © 2022 Fatemeh Tahghighi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Cryopyrin-associated periodic syndromes (CAPS) are a group of autoinflammatory disorders caused by a mutation in the NLRP3 (CIAS1) gene located on the long arm of chromosome 1. CAPS are a spectrum of disorders with a range of severity. The moderate form of the CAPS is Muckle–Wells syndrome, often inherited as an autosomal dominant trait. The main clinical manifestations include recurrent episodes of fever, urticaria-like rash, and ocular and articular involvement. The severe form of the CAPS is the chronic infantile neurological cutaneous and articular (CINCA) disease that is presented with urticaria-like rash, mental delay, arthritis, and sensorineural hearing loss [1–5].

Formation of NLRP3 inflammasome leads to caspase 1-mediated release of the proinflammatory cytokines such as IL-1B and IL-18. Since NLRP3 mutations can result in increased inflammasome activation and IL-1 production, IL-1 targeted therapies are frequently used in the aforementioned disorders. Case Presentation. We report two cases of CAPS in which the diagnosis was confirmed by genetic tests and an evaluation of the therapeutic response to anti-tumor necrosis factor (anti-TNF) agents. Conclusion. IL-1 inhibitors are highly effective in treating CAPS patients. Most patients with severe symptoms such as neurologic involvement improve with IL-1 blockade. Anti-TNF agents might be effective in reducing mild manifestation; however, they are not effective in improving more severe complications.

1. Introduction

Cryopyrin-associated periodic syndromes (CAPS) are a group of autoinflammatory disorders caused by a gain-of-function mutation in the NLRP3 (CIAS1) gene located on the long arm of chromosome 1. CAPS are a spectrum of disorders with a range of severity. The moderate form of the CAPS is Muckle–Wells syndrome, often inherited as an autosomal dominant trait. The main clinical manifestations include recurrent episodes of fever, urticaria-like rash, and ocular and articular involvement. The severe form of the CAPS is the chronic infantile neurological cutaneous and articular (CINCA) disease that is presented with urticaria-like rash, mental delay, arthritis, and sensorineural hearing loss [1–5].

Formation of NLRP3 inflammasome leads to caspase 1-mediated release of the proinflammatory cytokines such as IL-1B and IL-18. Since NLRP3 mutations can result in increased inflammasome activation and IL-1 production, IL-1 targeted therapies are used frequently in the patients. Interleukin 1 receptor antagonists such as anakinra can improve CAPS symptoms and prevent major complications such as hearing loss and amyloidosis [6–9]. Some patients with CAPS show partial response to IL-1 blockade. Other biologics such as anti-tumor necrosis factor (anti-TNF) agents are less effective than IL-1 inhibitors. In a few patients, anti-TNF agents have been able to result in partial response and improvement. TNF-α may play a role in regulating and activating the NLRP3 inflammasome [1, 2, 10].

We will describe two cases of CAPS and evaluate the responses to anti-TNF agents and IL-1 inhibitors. The current study aims to describe the relative effectiveness of anti-TNF agents in improving CAPS symptoms,
highlighting the role of TNF-α in the pathogenesis of the disorders.

2. Case 1

A 1-year-old boy was brought to our clinic with joint pain and swelling in his left ankle and knees that had lasted for more than 14 days. Since birth, he had had a recurrent urticarial rash that was not triggered by cold or other physical stimuli (Figure 1). Often presented with high-grade fever, the rash lasted 24 hours and resolved without scarring. Additionally, he was treated with antihistamines for a long time due to a history of chronic urticaria. He was born premature and admitted for 60 days in the neonatal intensive care unit (NICU). His parents were not blood relatives. His older brother has a history of chronic atopic dermatitis. On examination, neurodevelopmental evaluation result was normal, but his weight and height were below the 3rd percentile for his age. He had significant synovial hypertrophy in both knees. No hepatosplenomegaly or lymphadenopathy was present. Other physical examinations indicated normal results. However, laboratory findings showed leukocytosis, anemia, and thrombocytosis. More- ever, there was an increase in acute phase reactants. The patient’s laboratory tests are listed in Table 1. Both chest X-ray and abdominal ultrasonography were normal. The left ankle and right knee sonography showed mild to moderate effusion and synovial hypertrophy.

Echocardiography expressed normal ventricular function and no pericardial effusion. He had normal bone marrow aspiration and biopsy. Due to prolonged fever, arthritis, and an increase in acute phase reactants, the diagnosis of systemic juvenile idiopathic arthritis was established for him. Therefore, he was treated with prednisolone, methotrexate, and naproxen. At the age of three, he was readmitted to the hospital because of his inability to walk due to arthritis, persistent fever, and urticarial rash. An X-ray of the knees indicated metaphyseal irregularity, widening of growth plate, and soft tissue swelling (Figure 2). In three-phase bone scintigraphy, there were inflammatory processes in several joints, including the right elbow and both knees (Figure 3). At that time, the diagnosis of autoinflammatory disorders, especially CAPS, was made for him. A genetic test was performed, and the whole exome sequencing (WES) identified a new variant in exon 5 of NLRP3 (NM-001079821: c. G1060T, p. A354S) (9). He was heterozygous for this mutation, while his parents were homozygous wild type. It was a de novo mutation. The patient was heterozygous for this mutation, while his parents were homozygous wild type. It was a de novo mutation. The patient was treated with etanercept at a dose of 0.8 mg/kg per week subcutaneously because anakinra was not available at the time. After six months of anti-TNF therapy, joint involvement relatively improved. Not only could he walk but also his fever was under control. However, he had a mild effusion in his left knee during treatment with etanercept. Furthermore, the urticarial-like rash had decreased but did not resolve completely. At the age of 4, he developed both eyelids’ swelling and erythema, which decreased his visual acuity (Figure 4). Ophthalmologic examination showed retinal vasculitis and severe optic disc edema. When anakinra was available, treatment was initiated. Anakinra was initiated at a dose of 1 mg/kg subcutaneously daily. After one month, a considerable response was observed, while full recovery occurred after four months. We reported this case in detail in our previous report [11].

3. Case 2

A 2-year-old girl was referred to our clinic for periodic fever and rash. Fever often worsened at night; besides, she had abdominal pain during some febrile episodes. She had had a recurrent purpuric urticarial rash since three months (Figure 1). The rash was usually accompanied by the onset of fever. The immunological evaluation result was normal, and she had been treated with antihistamines due to a history of chronic urticarial rash. She did not have a history of seizures, joint involvement, or conjunctivitis. She was the third child of the family. Her parents were blood relatives, and her siblings were healthy. She was hospitalized at the age of 1, with a diagnosis of sepsis and at the age of 3, for an evaluation of fever with unknown origin. Physical examinations revealed a high-grade fever, urticarial rash, and subcutaneous nodule in the subcostal and inguinal region. No hepatosplenomegaly or lymphadenopathy was present. There were no conjunctivitis, arthritis, or mental and physical disability. Neurologic examination results were normal. However, laboratory findings reported leukocytosis, anemia, and thrombocytosis. Erythrocyte sedimentation (ESR) and C-reactive protein (CRP) levels were elevated. The patient’s laboratory tests are listed in Table 1. Chest X-ray and echocardiography were normal. Three-phase bone scintigraphy did not report clear evidence of inflammatory or active bone lesion. Skin biopsy showed dermis vessels with plump endothelial cells, intramural and perivascular neutrophils, and few eosinophils with no evidence of granuloma or necrosis. Also, she had normal bone marrow aspiration and biopsy. She had been treated with prednisolone and ibuprofen due to a diagnosis of systemic juvenile idiopathic arthritis; however, fevers and skin rashes had not been taken under control. The autoinflammatory disease was suggested as a diagnosis. Whole exome sequencing reported a variant in exon 3 NLRP3 gene (NM_001127462: c. G1057C, p. V353L). She was heterozygous for this variant. It was a de novo mutation. She was treated with etanercept at a dose of 0.8 mg/kg per week subcutaneously. Thereafter, fever was relatively controlled, but the rash did not respond to anti-TNF therapy. Relapse occurred after four months of treatment with etanercept. Anakinra was initiated at a dose of 1 mg/kg subcutaneously daily, and a dramatic response was observed after two months.

The signs and symptoms of the two patients are compared in Table 2.

4. Discussion

It is important to know that autoinflammatory syndromes are rare; however, they should be considered in any patient with recurrent or persistent inflammation. Most patients with these disorders experience delays in diagnosis. Our first
patient had a fever, urticarial rash, and arthritis. He had been treated with systemic juvenile idiopathic arthritis (SJIA) diagnosis, but he was diagnosed with CAPS after further evaluation. The second patient had a recurrent fever and urticarial rash, but there was no joint involvement. She was initially treated with a diagnosis of SJIA, but her final diagnosis was Muckle–Wells syndrome after more evaluation and genetic tests.

**Figure 1:** Urticaria-like rash on face and extremities. (c) At 10 months old, (b) at 3 years old (the first case), and (a) at 2 years old (the second case).

**Table 1:** Laboratory tests of cryopyrin-associated periodic syndromes cases.

| LAB (unit) | Case 1 | Case 2 |
|-----------|--------|--------|
| WBC (µl)  | 16100  | 16000  |
| Hemoglobin (g/dl) | 7.5 | 9.5 |
| HCT (%) | 25.4 | 35.5 |
| Platelets (µl) | 567000 | 703000 |
| GRA (%) | 52 | 45 |
| LYM (%) | 40 | 35 |
| MON (%) | 3.9 | 14.1 |
| EOS (%) | 4 | 4.9 |
| BASO (%) | 0.1 | 1 |
| ESR (mm/hr) | 60 | 112 |
| CRP (mg/l) | 75 | 180 |
| AST (U/l) | 17 | 29 |
| ALT (U/l) | 11 | 30 |
| LDH (U/l) | 347 | 450 |
| Uric acid (mg/dl) | 3.3 | 4 |
| Ferritin (ng/ml) | 29 | 167 |
| BUN | 35 | 40 |
| Creatinine | 0.4 | 0.5 |
| ANA | N | N |
| CANCA | N | N |
| P-ANCA | N | N |
| ACE | 34 | — |
| RF | N | N |
| ACPA | N | — |
| IgG (g/l) | 1667 | 1740 |
| IgM (g/l) | 122 | 160 |
| IgA (g/l) | 181 | 178 |
| IgE (g/l) | 1021 | 1210 |
| IL6 (IU/l) | 28 | 50 |

LAB: laboratory; WBC: white blood cell count; HCT: hematocrit test; GRA: granulocytes; LYM: lymphocytes; MON: monocytes; EOS: eosinophils; BASO: basophils; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; BUN: blood urea nitrogen; ANA: antinuclear antibody; C-ANCA: antineutrophil cytoplasmic autoantibody; P-ANCA: perinuclear anti-neutrophil cytoplasmic antibodies; ACE: angiotensin-converting enzyme; RF: rheumatoid factor; ACPA: anti-citrullinated peptide antibody; Ig: immunoglobulin; IL: interleukin; N: negative.
The symptoms of cryopyrin-associated periodic fever syndromes are variable and presented with a broad range of clinical manifestations [2]. Inheritance of CAPS is usually autosomal dominant. Additionally, the disease has a spectrum of symptoms in different generations. The severity of symptoms increases as the age goes up. For example, the disease may be seen as amyloidosis and renal failure in the first generations. However, in younger children, urticaria, and fever may be observed. CNS manifestations are one of the common clinical presentations of CINCA. In Muckle–Wells syndrome, joint involvement is mild to moderate, while severe joint involvement and deformity are more common in CINCA syndrome. Our first case had severe joint disease correlated with CINCA syndrome, but CNS manifestations and mental disability were not observed. Our first case also had optic disc edema that is usually presented in CINCA syndrome [11–15].

In young children with Muckle–Wells, hearing loss and amyloidosis does not usually occur, and the only manifestation of the disease may be recurrent urticarial rash and fever. The second case had typical symptoms of Muckle–Wells, including urticaria-like rash and fever. Nevertheless, she did not have joint involvement. The primary treatment for CAPS is the IL-1 inhibitors, which can completely relieve the disease’s symptoms [10, 16, 17].

Both of our patients were initially treated with anti-TNF agents because IL-1 inhibitors were unavailable. In the first case, joint involvement and fever were resolved with anti-TNF agents; yet, the urticarial rash did not respond to this therapy, and optic disc edema occurred during the anti-TNF therapy. The second case was initially treated with an anti-TNF agent (etanercept) too. Nevertheless, the response was transient, and relapse occurred after four months. Some of the CAPS manifestations, such as fever, were resolved with anti-TNF agents, but some of them did not resolve fully, and relapse might occur. After IL-1 inhibitors therapy, all of the symptoms resolved dramatically and entirely.

### Table 2: Signs and symptoms of cryopyrin-associated periodic syndromes cases.

| Sign and symptoms            | Case 1 | Case 2 |
|------------------------------|--------|--------|
| Urticarial rash              | +      | +      |
| Conjunctivitis               | −      | −      |
| Dysmorphic features          | −      | −      |
| Joint involvement            | +      | −      |
| Hearing loss                 | −      | −      |
| Visual loss                  | +      | −      |
| Aseptic meningitis           | −      | −      |
| Optic disc edema             | +      | −      |
| Intellectual disability      | −      | −      |

Figure 2: Knees X-ray shows metaphyseal irregularity, widening of growth palate, and soft tissue swelling (the first case).

Figure 3: Three-phase bone scintigraphy shows inflammatory processes in several joints, including both left and right knees. (a) Immediate phase and (b) delayed phase (for the first case).

Figure 4: Swelling and erythema of both eyelids (the first case).
TNF-α might play a regulatory role upstream of the NLRP3 inflammasome. Caspase 11-mediated inflammasome activation participates in driving the production of TNF-α. However, the cellular source of the TNF-α and the mechanism of generation are unclear. In patients with CAPS, proinflammatory cytokines such as IL-1B play an essential role in the development of symptoms. At least half of the patients with CAPS have a range of neurological manifestations at some course of illness. A few studies have shown that IL-1 inhibitors are effective for treating neurological symptoms and preventing severe CNS complications. The most common neurological manifestations in CAPS are headache, aseptic meningitis, seizures, papilledema, and hearing loss. Serious neurological complications include optic atrophy and mental disability. Skin rash, fever, and arthritis are milder CAPS symptoms [17–20].

5. Limitations

In case reports, causal inference is not plausible. Response to the treatment could be a mere coincidence. Accordingly, the effects of anti-TNF agents on clinical presentations from the current case report of CAPS cannot be generalized.

6. Conclusion

Based on our experiences in this study, although TNF-α inhibitors effectively reduced mild manifestations such as fever and rash, they were not effective for improving more serious complications like papilledema and arthritis. Since CAPS is a rare disease, there are few reports of this disorder. Future studies are needed to evaluate the effect of such medical treatments on improving the various symptoms of CAPS.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Consent

Written informed consent was obtained from the patients’ parents.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Acknowledgments

The authors would like to thank the parents for giving permission to publish the report of this case.

References

[1] W. Tatjana and J. B. Kuenmerle-Deschner, “Diagnosis and management of the cryopyrin-associated periodic syndromes (CAPS): what do we know today?” Journal of Clinical Medicine, vol. 10, p. 128, 2021.

[2] H. Malcova, Z. Strizova, T Milota et al., “IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives,” Frontiers in Immunology, vol. 11, Article ID 619257, 2021.

[3] A. Gupta, S. K. Tripathy, R. H. Phulware, S. Arava, and N. K. Bagri, “Cryopyrin-associated periodic fever syndrome in children: a case-based review,” International Journal of Rheumatic Diseases, vol. 23, no. 2, pp. 262–270, 2020.

[4] S. Hansmann, E. Lainka, G. Hornneff et al., “Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative,” Pediatric Rheumatology Online Journal, vol. 18, p. 17, 2020.

[5] Z. Ahmadinejad, S. Mansouri, V. Ziaee, Y. Aghighi, and M. H. Moradinejad, “A review on clinical, management and guideline for Iranian patients—part II,” Iranian Journal of Pediatrics, vol. 24, pp. 229–240, 2014.

[6] S. Torreggiani, G. Filocamo, and S. Esposito, “Recurrent fever in children,” International Journal of Molecular Sciences, vol. 17, no. 4, p. 448, 2016.

[7] A. Soriano, M. Soriano, G. Espinosa, R. Manna, G. Emmi, and L. Cantarini, “Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome: evidence-based approach and proposal of a practical guide,” Frontiers in Immunology, vol. 11, p. 865, 2020.

[8] E. C. Landmann and U. A. Walker, “Pharmacological treatment options for cryopyrin-associated periodic syndromes,” Expert Review of Clinical Pharmacology, vol. 10, no. 8, pp. 855–864, 2017.

[9] H. Nakanishi, Y. Kawashima, K. Kurima et al., “NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy,” Proceedings of the National Academy of Sciences, vol. 114, no. 37, pp. E7766–E7775, 2017.

[10] J. B. Kuenmerle-Deschner, H. Wittkowski, P. N. Tyrrell et al., “Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens,” Arthritis Research & Therapy, vol. 15, no. 3, p. R64, 2013.

[11] M. Vahedi, N. Parvaneh, S. Vahedi, M. Shahrooei, and V. Ziaee, “Identification of a new variant in NLRP3 gene by Whole exome sequencing in a patient with cryopyrin-associated periodic syndrome,” Case Reports in Immunology, vol. 2021, Article ID 2023119, 4 pages, 2021.

[12] E. Naz Villalba, E. Gomez de la Fuente, D. Caro Gutierrez et al., “Muckle-Wells syndrome: a case report with anNLRP3T348M mutation,” Pediatric Dermatology, vol. 33, no. 5, pp. e311–e314, 2016.

[13] Š. Fingerhutová, J. Fráňová, E. Hlaváčková et al., “Muckle-Wells syndrome across four generations in one Czech family: natural course of the disease,” Frontiers in Immunology, vol. 10, p. 802, 2019.

[14] J. B. Kümmerle-Deschner, P. N. Tyrrell, F. Reess et al., “Risk factors for severe Muckle-Wells syndrome,” Arthritis & Rheumatism, vol. 62, pp. 3783–3791, 2010.

[15] J. B. Kümmerle-Deschner, A. Koitschev, K. Ummenhofer et al., “Hearing loss in Muckle-Wells syndrome,” Arthritis & Rheumatism, vol. 65, no. 3, pp. 824–831, 2013.

[16] L. Maksimovic, J. Stirnemann, F. Caux et al., “New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes,” Rheumatology (Oxford, England), vol. 47, pp. 309-310, 2008.

[17] B. Kortus-Götze and H. Joachim, “Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-
1β-monoclonal antibody,” *Nephrology Dialysis Transplantation*, vol. 4, pp. 404-405, 2011.

[18] K. Aoyama, H. Amano, Y. Takaoka, R. Nishikomori, and O. Ishikawa, “Cryopyrin-associated periodic syndrome: a case report and review of the Japanese literature,” *Acta Dermato Venereologica*, vol. 92, no. 4, pp. 395–398, 2012.

[19] H. Kilic, S. Sahin, C. Duman et al., “Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome,” *European Journal of Paediatric Neurology*, vol. 23, no. 3, pp. 466–472, 2019.

[20] B. Banoth and F. S. Sutterwala, “Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes,” *Journal of Clinical Investigation*, vol. 127, no. 12, pp. 4235–4237, 2017.